Antiepileptic Drugs Market - Forecast(2022 - 2027)

Report Code: HCR 0142 Report Format: PDF + Excel

Antiepileptic Drugs Market Overview

Antiepileptic Drugs Market size is estimated to reach $21.4 billion by 2027, growing at a CAGR of 2.6% during the forecast period 2022-2027. Antiepileptic drugs are also delineated as anticonvulsants that are taken into account to treat seizure disorders which are commonly known as “Epilepsy.” This condition can set many complications like muscle stiffness, atypical sensations, abnormal behavior, and others in motion. At worst patient may slide into oblivion. There is no one particular cause of epilepsy. It can be stimulated by genetic influence, brain injuries, infections prenatal injury, and many more. There are several anticonvulsants or antiepileptic drugs such as valproic acid, and eslicarbazepine acetate (= aptiom, zebnix) which are leading medicines in the treatment of epilepsy.  The effect of uridine glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics is widely acknowledged. Furthermore, Therapeutic drug monitoring assists in epilepsy treatments by measuring the medicine amount present in the blood. The antiepileptic drugs market outlook is exceptionally enchanting with shooting up demand. Augmenting consumption of alcohol, stress, and depression bound with desires for a successful life, and proliferating incidences of serious injuries while impaired with alcohol and drugs are factors set to drive the growth of the Antiepileptic Drugs Industry for the period 2022-2027.

Report Coverage

The report: “Antiepileptic Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antiepileptic Drugs Market

By Drug Type: First generation (Mysoline, Zarontin, Carbatrol, Topamax, Luminal, and others), Second generation (=Vimpat, Lyrica, Keppra, Aptiom, Banzel, Fycompa, and others), and Third generation drugs.
By Form: Dry (=tablets or pills) and Liquid.
By Administered route: Oral, Vein injections/Intravenous.
By Distribution Channel: Offline channels (=Hospital Pharmacies, Retail Pharmacies, Drug stores, and others), Online Platforms.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

  • Geographically, the North America Antiepileptic Drugs Market accounted for the highest revenue share in 2021. It is owing to the presence of robust infrastructural capabilities which enhances the diagnosis to cure ratio, supplementing the market growth. Nevertheless, Asia-Pacific is poised to dominate the market over the period 2022-2027.
  • The far-reaching prevalence of epilepsy seizures is said to be the preeminent driver driving the growth of the Antiepileptic Drugs Market. Besides, several side-effects connected with anticonvulsants are said to reduce the market growth.
  • A detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Antiepileptic Drugs Market report.

 Antiepileptic Drugs Market- Geography (%) for 2021

Antiepileptic Drugs Market

For more details on this report - Request for Sample

Antiepileptic Drugs Market Segment Analysis-By Drug Type

The Antiepileptic Drugs Market based on the drug type can be further segmented into the first generation (Mysoline, Zarontin, Carbatrol, Topamax, luminal, and others), second-generation (=Vimpat, Lyrica, Keppra, Aptiom, Banzel, Fycompa, and others), and third-generation drugs. The second-generation segment held the largest share in 2021. The growth is owing to higher effectiveness as compared to other categories of drugs. These drugs work by either controlling the impulse or enhancing the inhibition. Moreover, they are capable of affecting the pore-forming membrane proteins commonly termed ion channels and varying the neurons' electrical activity. However, the third-generation drugs segment is estimated to be the fastest-growing with a CAGR of 3.4% over the forecast period 2022-2027. This growth is owing to augmenting focus of companies on the production of third-generation drugs. Considering the before long expiration of patents on second-generation drugs companies are stepping up their efforts and allocating the innumerable amount of funds to research and development activities.

Antiepileptic Drugs Market Segment Analysis-By Distribution Channel

The Antiepileptic Drugs Market based on distribution channels can be further segmented into offline channels (=hospital pharmacies, retail pharmacies, drug stores, and others), and online platforms. The offline segment held the largest share in 2021. The growth is owing to the full-fledge and all-encompassing nature of offline facilities as compared to online. Offline platforms like hospitals and retail pharmacies have their presence in pastoral areas also which makes them the first point of contact for more than 40% of the population because 45-46% of the world population still reside in the countryside as of 2021. Moreover, the availability of top-flight doctors and the well-equipped nature of hospitals encourage people to undergo treatments which can be a driving factor in the growth of the respective market. Nevertheless, the offline segment is estimated to be the fastest-growing with a CAGR of 3.8% over the forecast period 2022-2027. This growth is owing to the unbelievable pace at which digitalization is spreading across rural areas. With 24/7 access to networks, people are becoming more technology-friendly. Consequently, they are choosing online pharmacies over offline as buying online is much more convenient and saves time also.

Antiepileptic Drugs Market Segment Analysis-By Geography

The Antiepileptic Drugs Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 36% of the overall market in 2021. The growth in this segment is owing to the factors such as to-notch quality of healthcare infrastructure which is promoting better treatment and diagnosis rates. The U.S. and Canada have a network of world-class hospitals and research labs which gives this segment a strategic edge over the rest of the world in extending better patient care and novel drug discovery. On another hand, owing to high living standards people due to affluent economies people living in these countries are considered to be more health-conscious and financially capable to undergo curing treatments. However, Asia-Pacific is estimated to offer lucrative growth opportunities over the forecast period 2022-2027. This growth is owing to an escalation in the prevalence of neurological disorders. Many people in Asian nations like India, Bangladesh, Pakistan, Nepal, and others still live in impoverished areas with no adequate infrastructure. Therefore, to delude the reality and forget their day-to-day problems they tend to associate with alcohol and marijuana which brings them one step closer to mental concussion and epileptic disorders. Additionally, other nations like Japan, China, Australia, and New Zealand have their fair share in the growth of their respective market because prospering economies of these countries allows them to spend billions of dollars on research.

Antiepileptic Drugs Market Drivers

Broadening cases of stress, depression, and accidents are Anticipated to Boost Product Demand.

We all are living in a dynamic era where one has to put constant efforts in order to keep up with ever-growing competition otherwise, they may lag. In their pursuit of achieving something big or living a successful life people are constantly driving them into depression. This constant unrest is one of the biggest reasons behind mental disorders. According to a WHO study, around 3.8-4% of the world population is afflicted with depression. Most depressed people slide themselves into serious epileptic complications. On another hand, severe injuries connected with accidents are another major factor driving the growth in the antiepileptic drugs market. a study by the Center for Disease Control (CDC) claimed that more than 28-29% of brain injuries are linked to road accidents. Consequently, heightening road tragedies can be a factor of growth in the respective market.

A massive push of companies in the development of novel third-generation drugs is Expected to Boost Product Demand.

It should not come as a surprise that epileptic seizures are more common in the elderly population. Therefore, as the old-age population of the world is anticipated to touch the 1-2 billion mark within a few years various companies in their respective fields have stepped up their efforts to meet the rising demand and make profits. Market players are allocating innumerable flows of hard cash into research and development processes to fabricate a more effective and stable alternative to 2nd generation drugs. Besides, patent expiration several second-generation medications are imminent which is another potential driver for the growth of the antiepileptic drugs market. Furthermore, an active push has been made in treating the associated ailments which come along with epilepsy. For example, LGS ( Lennox-Gastaut Syndrome), a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-resistant seizures with high morbidity as well as a serious impairment of neurodevelopmental, cognitive, and motor functions affects nearly 30-50,000 patients in the U.S.

Antiepileptic Drugs Market Challenges

Several health hitches accompanied by these drugs are Anticipated to Hamper Market Growth.

In a few parts of the world talking about such neurological abnormalities is still considered taboo. Therefore, rather than revealing and undergoing a treatment people try to hide such complications which can strangle the growth in the respective market. Moreover, there are several health hitches of antiepileptic drugs that refrain people from consuming them. These medications can set hepatoxicity, nephrolithiasis, obesity, mental slowdown, skin problems, and many more in motion which is anticipated to cripple the growth of the antiepileptic drugs market. Furthermore, epilepsy-resistant drugs are a huge concern for various public health authorities as the numbers for the same are growing at a rampant pace. As in the globe, around 1 million people have shown resistance to such drugs which would force newer lines of medications to develop.  

Antiepileptic Drugs Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antiepileptic Drugs Market. Key companies of this market are-

  1. Abbott Laboratories
  2. Johnson & Johnson
  3. Sanofi S.A.
  4. Valeant Pharmaceuticals International
  5. UCB Pharma
  6. GlaxoSmithKline
  7. Pfizer Inc.
  8. Novartis International AG.
  9. Sunovion Pharmaceuticals
  10. Cephalon Inc.

Recent Developments

  • In April 2022, Neuro-Pace announced the first patient being treated in a Pivotal Study evaluating the RNS Systems in adolescents aged between 12 through 17. Additionally, the following technology comes as an alternative to the already available anti-epileptic drugs. As per various research published by the company around 1 million people live through drug-resistant epilepsy. The RNS System has demonstrated unprecedented seizure reduction and improved quality of life in adults with drug-resistant focal epilepsy.
  • In May 2022, JAMA Neurology published Phase-3 study results on the efficacy and safety of FINTEPLA Oral Solution for LGS ( Lennox-Gastaut Syndrome ). Multi-center, double-blind, placebo-controlled, parallel-group, randomized Phase 3 trial demonstrating that FINTEPLA 0.7 mg/kg/day, when added to a patient's current anti-epileptic treatment regimen for seizures associated with LGS, is effective in reducing the frequency of drop seizures.
  • On November 12, 2020, Brussels, Belgium-based biopharmaceutical company “Union Chimique Belge”, commonly known as UCB announced the acquisition of “Handl Therapeutics.” Handl is headquartered in Leuven, Belgium, and is famous for its gene therapies which help in the treatment of neurodegenerative illnesses.

Relevant Links:

Brain Tumor Treatment Market – Forecast (2022 - 2027)
Report Code: HCR 0257

Rare Neurological Disease Treatment Market-Forecast (2022 – 2027)
Report Code: HCR 42071

Generic Drugs Market- Forecast (2022-2027)
Report Code- HCR 0217 

For more Lifesciences and Healthcare related reports, please click here

1. Antiepileptic Drugs Market Overview
    1.1 Definitions and Scope
2. Antiepileptic Drugs Market- Executive Summary
3. Antiepileptic Drugs Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Antiepileptic Drugs Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Antiepileptic Drugs Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Antiepileptic Drugs Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Antiepileptic Drugs Market – By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Antiepileptic Drugs Market- By Drug Type (Market Size –$Million/$Billion) 
    8.1 First Generation
        8.1.1 Mysoline
        8.1.2 Zarontin
        8.1.3 Carbatrol
        8.1.4 Topamax
        8.1.5 Luminal
        8.1.6 Others
    8.2 Second Generation
        8.2.1 Vimpat
        8.2.2 Lyrica
        8.2.3 Keppra
        8.2.4 Aptiom
        8.2.5 Others
    8.3 Third- Generation
9. Antiepileptic Drugs Market- By Administrative Route (Market Size –$Million/$Billion) 
    9.1 Oral
    9.2 Vein Injections
10. Antiepileptic Drugs Market- By Distribution Channels (Market Size –$Million/$Billion) 
    10.1 Offline Channels
    10.2 Online Channel
11. Antiepileptic Drugs Market- Form (Market Size –$Million/$Billion) 
    11.1 Dry
    11.2 Liquid
12. Antiepileptic Drugs Market - By Geography (Market Size -$Million/Billion)
    12.1 North America
        12.1.1 U.S
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 Germany
        12.2.2 France
        12.2.3 UK
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Japan
        12.3.3 South Korea
        12.3.4 India
        12.3.5 Australia & New Zealand
        12.3.6 Rest of APAC
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. Antiepileptic Drugs Market - Market Entropy
    13.1 New product launches
    13.2 M&A's, collaborations, JVs and partnerships
14. Antiepileptic Drugs Market – Industry Competition Landscape (Premium)
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key Companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Antiepileptic Drugs Market – Key Company List by Country Premium (Premium)
16. Antiepileptic Drugs Market - Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies
List of Tables
Table 1: Antiepileptic Drugs Market Overview 2021-2026
Table 2: Antiepileptic Drugs Market Leader Analysis 2018-2019 (US$)
Table 3: Antiepileptic Drugs Market Product Analysis 2018-2019 (US$)
Table 4: Antiepileptic Drugs Market End User Analysis 2018-2019 (US$)
Table 5: Antiepileptic Drugs Market Patent Analysis 2013-2018* (US$)
Table 6: Antiepileptic Drugs Market Financial Analysis 2018-2019 (US$)
Table 7: Antiepileptic Drugs Market Driver Analysis 2018-2019 (US$)
Table 8: Antiepileptic Drugs Market Challenges Analysis 2018-2019 (US$)
Table 9: Antiepileptic Drugs Market Constraint Analysis 2018-2019 (US$)
Table 10: Antiepileptic Drugs Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Antiepileptic Drugs Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Antiepileptic Drugs Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Antiepileptic Drugs Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Antiepileptic Drugs Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Antiepileptic Drugs Market Value Chain Analysis 2018-2019 (US$)
Table 16: Antiepileptic Drugs Market Pricing Analysis 2021-2026 (US$)
Table 17: Antiepileptic Drugs Market Opportunities Analysis 2021-2026 (US$)
Table 18: Antiepileptic Drugs Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Antiepileptic Drugs Market Supplier Analysis 2018-2019 (US$)
Table 20: Antiepileptic Drugs Market Distributor Analysis 2018-2019 (US$)
Table 21: Antiepileptic Drugs Market Trend Analysis 2018-2019 (US$)
Table 22: Antiepileptic Drugs Market Size 2018 (US$)
Table 23: Antiepileptic Drugs Market Forecast Analysis 2021-2026 (US$)
Table 24: Antiepileptic Drugs Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 26: Antiepileptic Drugs Market By Type, Revenue & Volume,By First Generation Drugs, 2021-2026 ($)
Table 27: Antiepileptic Drugs Market By Type, Revenue & Volume,By Second Generation Drugs, 2021-2026 ($)
Table 28: Antiepileptic Drugs Market By Type, Revenue & Volume,By Pipeline Drugs, 2021-2026 ($)
Table 29: North America Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 30: South america Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 31: Europe Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 32: APAC Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 33: Middle East & Africa Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 34: Russia Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 35: Israel Antiepileptic Drugs Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 36: Top Companies 2018 (US$)Antiepileptic Drugs Market, Revenue & Volume
Table 37: Product Launch 2018-2019Antiepileptic Drugs Market, Revenue & Volume
Table 38: Mergers & Acquistions 2018-2019Antiepileptic Drugs Market, Revenue & Volume

List of Figures
Figure 1: Overview of Antiepileptic Drugs Market 2021-2026
Figure 2: Market Share Analysis for Antiepileptic Drugs Market 2018 (US$)
Figure 3: Product Comparison in Antiepileptic Drugs Market 2018-2019 (US$)
Figure 4: End User Profile for Antiepileptic Drugs Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Antiepileptic Drugs Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Antiepileptic Drugs Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Antiepileptic Drugs Market 2018-2019
Figure 8: Ecosystem Analysis in Antiepileptic Drugs Market 2018
Figure 9: Average Selling Price in Antiepileptic Drugs Market 2021-2026
Figure 10: Top Opportunites in Antiepileptic Drugs Market 2018-2019
Figure 11: Market Life Cycle Analysis in Antiepileptic Drugs Market
Figure 12: GlobalBy TypeAntiepileptic Drugs Market Revenue, 2021-2026 ($)
Figure 13: Global Antiepileptic Drugs Market - By Geography
Figure 14: Global Antiepileptic Drugs Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 15: Global Antiepileptic Drugs Market CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 17: US Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 30: Brazil Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 59: U.K Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 92: China Antiepileptic Drugs Market Value & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Antiepileptic Drugs Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Antiepileptic Drugs Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Antiepileptic Drugs Market Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Antiepileptic Drugs Market 
Figure 130: Developments, 2018-2019*Antiepileptic Drugs Market 
Figure 131: Company 1 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Antiepileptic Drugs Market Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Antiepileptic Drugs Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Antiepileptic Drugs Market Net Sales Share, By Geography, 2018 (%)